comparemela.com

Page 4 - கேமிலோ சாந்தனா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Universidad brasileña pide autorización para probar otra vacuna

Universidad brasileña pide autorización para probar otra vacuna
sinembargo.mx - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sinembargo.mx Daily Mail and Mail on Sunday newspapers.

Workers Party pursues herd immunity policy as Brazil tops 400,000 COVID deaths

Scientists Support Brazil s Move to Ban Sputnik V COVID Vaccine

Scientists support the Brazilian drug regulator s decision to block the import of the Russian COVID vaccine Sputnik V due to seeing it carried a live version of a common cold-causing virus. Top virologist Angela Rasmussen said that it raises concerns on the integrity of the manufacturing processes, according to a CBS News report. Rasmussen added that it could be a safety issue for people with weaker immune systems if it were widespread. Brazil s health authority announced earlier this week that it would not recommend importing the Russian COVID vaccine despite the urgent need for vaccines in the country. All five of Anvisa s directors voted against the importing of the vaccine, according to The New York Times report.

Brazil s Anvisa decides against the Russian Sputnik V vaccine

Anvisa s board convened Monday as mandated by Supreme Federal Court (STF) Justice Ricardo Lewandowski, who had given the agency 30 days to rule on the matter Brazil s National Health Surveillance Agency (Anvisa) Monday recommended against the import of the Russian-made Sputnik V vaccine to fight the covid-19 pandemic, citing lack of proper documents required for approval as well as other health risks the antidote may imply. Anvisa s board convened Monday as mandated by Supreme Federal Court (STF) Justice Ricardo Lewandowski, who had given the agency 30 days to rule on the matter and denied subsequent requests to extend the deadline. A group of Anvisa experts travelled to Russia on April 16 to collect more information about the immunizer and arrived back last Saturday. Until then, Anvisa had informed that there was a lack of technical information on the safety and efficacy of the immunizer.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.